Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elecoglipron PK and Safety Study in Healthy Participants
NCT07723833Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elecoglipron in obesity and type 2 diabetes mellitus (T2DM) (8 cohorts), sponsored by AstraZeneca. Primary endpoints: Maximum observed drug concentration, Area under concentration-curve from time 0 to the last quantifiable concentration and 9 more. Started Jul 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07723833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723833.